Stockreport

RAP-219 Phase 2a Seizure Data and Planned Pivotal Trials Might Change The Case For Investing In Rapport Therapeutics (RAPP) [Yahoo! Finance]

Rapport Therapeutics, Inc.  (RAPP) 
PDF Rapport Therapeutics recently presented new data and post hoc analyses from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures at the 2025 American Epi [Read more]